Danish Pharma Stock News

Rockwool (CPSE:ROCK B) has proposed at its upcoming April 15, 2026 AGM to cancel 4,346,560 repurchased class B shares, cutting nominal share capital and amending its Articles of Association. See our latest analysis for Rockwool. That capital reduction proposal comes after a weak stretch for the share price, with a 1 month share price return of a 20.19% decline and a 1 year total shareholder return of a 41.48% decline. This suggests momentum has been soft, even though the 3 year total...

As European markets navigate heightened uncertainty due to geopolitical tensions and soaring energy costs, the pan-European STOXX Europe 600 Index has seen a notable decline of 3.79%. Amidst these challenges, investors may find opportunities in stocks that appear undervalued based on their intrinsic value, offering potential for growth when market conditions stabilize.

FirstFarms FY 2025 Results: Margins Under Pressure As One Off Loss Hits Bottom Line FirstFarms (CPSE:FFARMS) has released its FY 2025 figures with third quarter revenue of DKK 91.7 million, basic EPS of DKK 0.03 on a trailing twelve month basis, and a trailing net profit margin of 0.09% compared with 2.8% a year earlier. Over recent periods, quarterly revenue has moved from DKK 107.4 million in Q3 2024 to DKK 91.7 million in Q3 2025, while basic EPS has swung between a loss of DKK 1.35 in Q1...

Wondering whether Jyske Bank at DKK 862.5 still offers value after a strong run, or if you might be late to the story? The share price has pulled back, with a 1.2% decline over the last week and a 10.1% decline over the last month. The 1 year return is 55.3% and the 5 year return is 215.1%. Recent coverage has focused on Jyske Bank's strong multi year share price performance, with attention on how the current pullback fits within a longer trend of gains such as the 99.1% 3 year return...

A.P. Møller - Mærsk has joined the new Torus Defence Supply Chain alliance to support UK defence logistics and digital military supply chains. The alliance brings together Maersk and other industry partners to work on sovereign defence capability and more resilient logistics for the UK. Separately, Maersk has received approval to amend its bylaws following a capital decrease, reflecting ongoing corporate restructuring. For investors watching CPSE:MAERSK B, these steps add fresh context to a...

Earlier this week, United Biotechnology and Novo Nordisk reported phase 2 data from China showing that UBT251, a once-weekly triple-agonist for GLP-1, GIP and glucagon, reduced HbA1c and body weight more than semaglutide and placebo in people with type 2 diabetes over 24 weeks. This outperformance versus semaglutide adds a potentially important next-generation obesity and diabetes candidate to Novo Nordisk’s pipeline just as competition, pricing pressure and generic semaglutide emerge in key...

Zealand Pharma (CPSE:ZEAL) is setting up a major U.S. research hub in Cambridge, Massachusetts, focused on AI-driven drug discovery and automation. The new site will support work on hybrid therapies, including antibody peptide conjugates and siRNAs, alongside the company’s peptide heritage. The expansion is intended to plug Zealand Pharma directly into the Boston life sciences cluster, with implications for scientific capabilities and hiring. For investors tracking Zealand Pharma at a share...

Lu AF28996 data puts H. Lundbeck (CPSE:HLUN B) pipeline in focus Fresh Phase 1b data for Lundbeck's Lu AF28996 in advanced Parkinson's disease, combined with new insights on multiple system atrophy, has pushed the drugmaker's research pipeline and long term neurology focus back into the spotlight. See our latest analysis for H. Lundbeck. At a share price of DKK37.64, Lundbeck has a 90 day share price return of a 12.47% decline and a 1 year total shareholder return of a 0.50% decline, so...

US FDA issued a formal warning letter to Novo Nordisk (CPSE:NOVO B) over shortcomings in safety monitoring and reporting for Ozempic and Wegovy. The letter cites failures in procedures for capturing and reporting serious and unexpected adverse events in the US market. Regulators are requiring corrective actions and have indicated that continued non compliance could trigger further enforcement. Novo Nordisk, listed as CPSE:NOVO B, is a global pharmaceutical company focused on diabetes and...

Lundbeck’s new clinical data on Lu AF28996 and the amlenetug program at the 2026 AD/PD conference has refocused attention on Genmab (CPSE:GMAB), given its collaboration role in developing amlenetug. See our latest analysis for Genmab. At a share price of DKK1,655.5, Genmab has a 1 day share price return of 1.13%, following a 30 day share price return decline of 10.68% and a 90 day share price return decline of 22.02%. The 1 year total shareholder return of 24.94% contrasts with weaker 3 and 5...

FLSmidth (CPSE:FLS) has drawn fresh attention after announcing a joint venture with local industrial group Texnopark in Uzbekistan, aimed at building a modular service centre for mining customers across Central Asia. See our latest analysis for FLSmidth. While the new Uzbekistan joint venture is grabbing attention, FLSmidth’s 1-day share price return of 3.87% comes after a softer 30-day share price return of 12.49%. This is set against a 1-year total shareholder return of 35.21% and a 5-year...

Tivoli (CPSE:TIV) has released its FY 2025 figures with Q3 total revenue of DKK 440.6 million, Basic EPS of DKK 15.1 and net income of DKK 86.3 million. This sets the tone for how the year is shaping up against a period where trailing 12 month net profit margin sat at 7.5% versus 8.6% the year before. The company has seen quarterly revenue move from DKK 69.9 million and a loss of DKK 99.2 million in Q1 2025 to DKK 375.1 million and net income of DKK 39.6 million in Q2 2025, before reaching...

Why Novozymes’ latest AGM matters for shareholders Novozymes (CPSE:NSIS B) has just wrapped up its Annual General Meeting, where shareholders approved the audited 2025 report and backed an ordinary dividend, putting capital returns and balance sheet choices in focus. See our latest analysis for Novozymes. Despite the AGM’s focus on dividends and capital structure, the share price return has been weaker recently, with a 30 day share price return of 9.66% and a year to date share price return...

Dividend announcement and contract renewal set the tone for ISS (CPSE:ISS) ISS (CPSE:ISS) has attracted fresh attention after announcing an annual dividend of DKK 3.20 per share, alongside renewing and expanding its integrated facilities services partnership with Virgin Media O2 in the UK. See our latest analysis for ISS. At a share price of DKK 222.6, ISS has seen a 3.25% year to date share price return. Its 1 year total shareholder return of 39.06% and 5 year total shareholder return of...

Bylaw changes and capital structure moves grab investor attention Embla Medical hf (CPSE:EMBLA) has drawn fresh interest after its 2026 Annual General Meeting approved share capital reductions, renewed board authorizations for future capital increases, and set out conditions for new share buyback and employee option programs. See our latest analysis for Embla Medical hf. Despite the AGM activity around buybacks and share capital, Embla Medical hf's share price has eased in recent months, with...

If you are wondering whether TORM is priced attractively right now, the key question is how its current share price lines up with the value of its underlying business. The stock last closed at kr.167.55, with returns of 5.6% over 7 days, a 3.4% decline over 30 days, 33.8% year to date and 44.4% over the past year. This raises fair questions about both upside potential and changing risk perceptions. Recent coverage has focused on TORM as a shipping name that remains on many investors'...

If you are wondering whether Ørsted at a last close of 138.0 is a bargain or a value trap, the key is understanding how different valuation methods line up on the stock. The share price has seen mixed performance, with a 7.8% return year to date contrasting with a 24.3% decline over the last year and a 54.7% and 74.6% decline over the past 3 and 5 years respectively. This can change how investors think about both risk and potential upside. Recent coverage around Ørsted has focused on its...

Novo Nordisk (CPSE:NOVO B) is back in focus after the FDA cleared its high dose Wegovy HD in the US, while patent protection for semaglutide in India expires, opening the door to lower cost rivals. See our latest analysis for Novo Nordisk. The FDA approval for Wegovy HD arrives at a time when short term sentiment has cooled, with a 30 day share price return of 23.72% and a 1 year total shareholder return decline of 53.81%, suggesting recent momentum has faded despite longer term gains over 5...

Vestas Wind Systems (CPSE:VWS) has attracted fresh attention after securing a firm turbine order for RWE's 1,380 MW Vanguard East offshore wind project in the United Kingdom, a long-dated contract extending into the next decade. See our latest analysis for Vestas Wind Systems. The share price is at DKK156.0 after a 1 day share price return of 1.33%. However, the year to date share price return shows a 12.68% decline, which contrasts with a 44.28% total shareholder return over the past year...

Dividend move puts Carlsberg (CPSE:CARL B) under the spotlight Carlsberg (CPSE:CARL B) has drawn fresh investor attention after its 16 March 2026 AGM approved a DKK 29.00 per share dividend for the 2025 financial year, highlighting capital return as a key focus. See our latest analysis for Carlsberg. The dividend decision comes as Carlsberg’s share price sits at DKK 792.0, with a 30 day share price return of 20.15% decline adding to a 1 year total shareholder return of 7.69% decline,...

Pandora AGM decisions put income and governance in focus Pandora (CPSE:PNDORA) used its 11 March 2026 AGM to approve a DKK 22.00 per share dividend, amend article 7.3 of its Articles of Association, and confirm that board member Christian Frigast will step down. See our latest analysis for Pandora. Pandora's recent AGM decisions on dividends, governance and board composition arrive after a sharp loss of momentum, with a 30 day share price return of 18% and a 1 year total shareholder return of...

Bavarian Nordic A/S recently reported full-year 2025 results, with sales rising to DKK 6,243.96 million and net income reaching DKK 1,375.38 million, alongside higher earnings per share from continuing operations. A day earlier, the company expanded its partnership with Serum Institute of India to transfer chikungunya vaccine manufacturing and explore further co-development, potentially broadening access in low- and middle-income countries. Next, we’ll assess how the chikungunya tech...

Insider and major shareholder moves put TORM (CPSE:TRMD A) in focus Recent activity around TORM (CPSE:TRMD A), including Oaktree Capital Group becoming a major shareholder and a significant share sale by the CEO, has drawn attention to ownership trends and governance signals. See our latest analysis for TORM. Alongside the change in major shareholders and insider selling, TORM’s share price momentum has been strong, with a 90 day share price return of 35.65% and a 1 year total shareholder...

AGM decisions put capital returns and share structure in focus Dampskibsselskabet Norden (CPSE:DNORD) has drawn fresh attention after its 11 March AGM approved a final 2025 dividend of DKK 2.00 per share and adopted share capital reduction amendments to its Articles of Association. See our latest analysis for Dampskibsselskabet Norden. Those AGM decisions come after a strong run in the share price, with a 90 day share price return of 16.5% and a 1 year total shareholder return of 53.48%. This...